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EDITORIAL REVIEW
Coagulation and renal disease
Intravascular thrombosis and coagulation occur in
association with a wide variety of clinical and experimental
renal lesions. The presence of fibrin and its derivatives in
vessels and glomeruli and the accompanying increase in
fibrin degradation products in the serum and urine suggests
that the normal process of intravascular deposition and
lysis of fibrin [1] is accelerated within renal vessels in certain
disease states.
Coagulation is of importance in two groups of disorders
in man. In the first the renal lesions are a manifestation of
some more generalized disorder of intravascular coagula-
tion. In such cases there is not usually any detectable
immunological damage within the kidney and the influence
of vasoactive substances on the microcirculation may be
very important in the pathogenesis of the renal lesions.
In the second group of disorders the kidney is the major
site of disease and localized thrombosis and fibrin deposi-
tion is superimposed on demonstrable immunological or
other endothelial damage.
Renal lesions caused by systemic intravascular coagulation
Whatever the cause of disseminated intravascular coagula-
tion, the kidney is an important target organ [21. Throm-
bosis itself will cause damage [3], and although some
lesions are reversible others are permanent. The nature
and duration of the stimulus which causes coagulation,
and the intensity and effectiveness of the local and gen-
eralized fibrinolytic activity which it provokes, may both
influence the resulting renal damage.
Glomerular damage resulting from thrombosis. Induction
of intravascular coagulation produces an almost immediate
reaction in mesangial cells characterized by swelling and
an increase in vacuoles, organelles, free ribosomes and
mitochondria [3]. These changes are accompanied by
phagocytosis of fibrin and secretion of basement membrane-
like material [3]. Within hours a marked increase in local
fibrinolytic activity (plasminogen activator) is present in
glomeruli [4] and cellular proliferation and other changes
appear within days [3].
The glomerular lesions which result from intravascular
coagulation cover the whole range of morphological reac-
tions seen in glomerulonephritis in man except for that of
extramembranous glomerulonephritis [3, 5]. Platelets and
fibrin may be seen in the lumen and endothelial cells show
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similar changes to those in mesangial cells. Subendotheiial
or intramembranous deposits may be translucent or con-
sist of dense fibrinoid material which probably represents
fibrin degradation products [3, 6]. Marked cellular pro-
liferation associated with increased deposition of mesangial
matrix may closely mimic the appearance of mesangial-
proliferative glomerulonephritis [7]. When these changes
are accompanied by layers of basement membrane-like
material within glomerular capillaries and by interposed
mesangial cell processes the lesion resembles mesangio-
capillary (membranoproliferative) glomerulonephritis [8].
Continuing deposition of basement membrane-like material
can cause complete occlusion of glomerular capillaries and
hyalinization of glomeruli [3, 5, 8].
The importance of vasoactive phenomena within the micro-
circulation. Vasomotor activity undoubtedly plays an
important part in determining the extent and severity of the
effects of intravascular coagulation on the kidney. Vaso-
motor factors may play a direct causal role in some situa-
tions. The evidence relating to participation of catechol-
amines is best defined in relation to two conditions, renal
cortical ischaemia which accompanies hemorrhagic shock
and the generalized Sanarelli-Schwartzman reaction. In
both the renal abnormalities can be prevented by blocking
adrenergic receptors [9, 10]. Although these two conditions
may be regarded as distinct their pathogenetic mechanisms
are probably very similar. Catecholamine levels are known
to be very high in endotoxic and hemorrhagic shock [11, 12]
and probably cause the intense vasoconstriction and decrease
in blood flow in the outer renal cortex in such states which
can be abolished by blocking adrenergic receptors [9]. The
Sanarelli-Schwartzman phenomenon which results from
two injections of bacterial endotoxin (or from a single
injection in a pregnant rabbit) can also be blocked by
blocking x-receptors [10]. It induces severe hypotension as
well as disseminated intravascular coagulation and resem-
bles a severe form of endotoxic shock.
The clinical counterpart of experimental shock is acute
renal failure associated with acute tubular necrosis. There
is now ample evidence of fibrin deposition in glomeruli
and intravascular coagulation in acute tubular necrosis
[13—18]. Catecholamine infusion will itself produce shock
and intravascular coagulation [19], which suggests that
excessive catecholamine secretion may cause intravascular
coagulation in acute renal failure associated with acute
tubular necrosis.
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The clinical counterpart of the Sanarelli-Schwartzman
phenomenon is renal cortical necrosis and this is parti-
cularly liable to occur in late pregnancy [20]. The experi-
mental form can be prevented by adrenergic blockade [10]
suggesting that catecholamines play an important part in
its pathogenesis.
Heparin will counteract the renal effects of both cate-
cholamine-induced shock [19] and the Sanarelli-Schwartz-
man phenomenon [21]. Because blocking agents completely
abolish the hemolysis accompanying catecholamine-induced
shock and heparin diminishes but does not abolish this
hemolysis [22], it is likely that the morphological changes
in the microcirculation induced by catecholamines cause
this form of intravascular coagulation and microangio-
pathic hemolysis.
The irregularities of the endothelial cells [22, 23],
together with segmental areas of constriction and dilatation
which are produced by infusion of vasoactive drugs [22—24],
probably form the morphological basis for thrombosis and
coagulation within the microcirculation. The associated
considerably diminished blood flow [23] would aggravate
intravascular thrombosis.
Thrombi tend to form immediately distal to an area of
segmental constriction [251 and maximal damage after
infusion of vasoactive drugs affects the same area [24].
The vasomotor effects of thrombi themselves cannot be
ignored as they may set up a vicious cycle. Intraarterial
thrombin is a potent vasoactive agent [26] and this effect
can be reduced by drugs which prevent platelet aggregation
[27]. Vasoactive factors are liberated by platelets and vaso-
active low molecular weight fibrin degradation products
could also contribute to the vessel changes.
There is also considerable evidence that the renin-angio-
tensin system may play a part in the pathogenesis of acute
renal failure. Plasma renin activity is markedly elevated in
clinical and experimental acute renal failure, including
those forms which have been attributed to a toxic effect
[28—31]. As both renal vasoconstriction and intravascular
coagulation may also occur in nephrotoxic renal failure
(Friedman and Kincaid-Smith, unpublished observations),
this may also prove to have an ischemic basis. Whether
the high renin levels play a primary or secondary role
in renal ischemia associated with acute tubular necrosis
is still a matter of debate [30]. Angiotensin infusion will
cause acute tubular necrosis [31], and as both ac-blocking
agents [9] and passive immunization against angiotensin-Il
[32] afford some degree of protection against acute renal
failure, catcholamines and angiotensin probably both play
a part in the pathogenesis of acute renal failure. Recent
work suggests that sympatho-adrenergic mechanisms may
cause the cortical hypoperfusion of hemorrhagic shock but
that the renin-angiotensin system plays a permissive role in
its pathogenesis [30].
Malignant hypertension. Vasoactive mechanisms within
the microcirculation may also initiate intravascular coagula-
tion in malignant hypertension. The onset of this condition
is marked by the development of irregular constrictions and
dilatations in the microcirculation [33] and by the appear-
ance of disseminated intravascular coagulation and a
microangiopathic hemolytic anemia [34—36]. Abnormal-
ities in the microcirculation may be the cause of intravas-
cular coagulation and microangiopathic hemolytic anemia
in this condition.
"Onion layering" in the intima almost identical with
that seen in malignant hypertension [37] precedes hyper-
tension in thrombotic microangiopathies associated with
disseminated intravascular coagulation. This change in
interlobular arteries could be the result of organization
of thrombi in a variety of disorders including malignant
hypertension [38, 39]. The morphology of interlobular
artery lesions in which red cells and fibrin may be trapped
within even the deepest layers of proliferating intimal cells
[38, 39] suggests that these vessel lesions may develop very
rapidly, and in allograft rejection they can be shown to
form in days [38, 39].
Pregnancy and pre-eclamptic toxemia. During preg-
nancy the kidney seems to be particularly susceptible to
damage by mechanisms involving intravascular coagulation.
Pregnant animals will develop a generalized Sanarelli-
Schwartzman reaction with only a single injection of
bacterial endotoxin and pregnant women are particularly
likely to develop renal failure as a result of infective or
hemorrhagic complications. Pre-eclamptic toxemia is the
most common complication of pregnancy and it probably
represents a chronic state of intravascular coagulation
[2, 40]. There is widespread fibrin deposition in renal vessels
and glomeruli [41] without demonstrable immunological
damage and fibrin degradation products are elevated. In
spite of the extent of subendothelial fibrin deposits in
severe cases, the clinical features of pre-eclamptic toxemia
usually reverse rapidly when the uterus is emptied. Although
it has been assumed that morphological lesions are also
reversible prospective biopsy studies show that they may
persist for months [42]. Six months after pregnancy glome-
rular lesions may closely resemble mesangiocapillary
(membrano-proliferative) glomerulonephritis [42] except
that proliferation is slight or absent, but biopsies may show
continuing resolution over a further period of a year or more.
Arterial lesions closely resembling those of severe hyper-
tension and perhaps due to organization of thrombi within
the renal vessels may develop in pre-eclamptic toxemia
when the blood pressure is not elevated and may persist
indefinitely [42].
Thrombotic microangiopathy including post-partum renal
failure and the hemolytic-uremic syndrome. In post-partum
renal failure disseminated intravascular coagulation is more
intense and vessel lesions are similar to, but more marked
than, the lesions seen in pre-eclamptic toxemia. Cases of
early post-partum renal failure form an intermediate group,
often having marked evidence of intravascular coagulation
but a better prognosis than those who present later [42].
Severe cases are usually rapidly fatal and resemble other
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cases of thrombotic microangiopathy in adults [43] except
for the predominant renal manifestations. The kidney is the
major site of damage which results from the intravascular
coagulation, and death in renal failure is usual unless this
can be reversed by heparin therapy [44—46]. On the one
hand thrombotic microangiopathy merges into the more
chronic disorder of thrombotic thrombocytopenic purpura
in which there is relatively more evidence of vascular
involvement in other organs [43, 47], and on the other hand
thrombotic microangiopathy in adults merges into the
hemolytic-uremic syndrome which is characteristically a
disease of young children. The latter term should probably
be confined to cases of the type which Gasser described [48].
Apart from the greater frequency of vessel lesions in
organs outside the kidney, the pathological features of
thrombotic microangiopathy in adults are very similar to
those in the hemolytic-uremic syndrome in children. The
vessel lesions may precede hypertension and then lead to a
fulminating form of hypertension particularly when throm-
botic microangiopathy follows pregnancy [46, 49]. Trans-
lucent subendothelial deposits, which are an important
ultrastructural finding in the thrombotic microangiopathies
and in other conditions where active fibrin deposition and
lysis occur, are discussed in a broader context below.
Vasoactive changes in the microcirculation may also be
important in this group of disorders. Some consider that
they represent the clinical counterpart of the experimental
Sanarelli-Schwartzman phenomenon [50] which can be
prevented by a-blocking agents.
The etiology of this group of disorders is unknown but
it has been postulated that they may represent an abnormal
immunological response to an antigen [51]. The antigen
could be of viral origin in the hemolytic-uremic syndrome
in childhood, of bacterial or viral origin in the spontaneous
cases of thrombotic microangiopathy, and perhaps related
to the products of conception in post-partum renal failure.
Modern immunological methods have failed to show any
antigen or antibody within the kidney in patients with
thrombothic microangiopathy or the hemolytic-uremic
syndrome. However, it is of interest that the translucent
subendothelial zones in lesions induced by virus infection
in mice [52] so closely resemble those in the hemolytic-
uremic syndrome and experimental thrombosis.
Lesions in which thrombosis is probably secondary
to immunological or other damage in vessels or glomeruli
In the second group of disorders in which thrombosis
participates in the formation of renal lesions, there is
usually evidence of underlying immunological or other
damage within the kidney.
Renal lesions in animals. Two naturally occurring dis-
eases in animals, namely, glomerulonephritis in NZB mice
[53] where the antigen is DNA [54, 55] and the Aleutian
disease of the mink in which the antigen is probably of
viral origin, show prominent fibrin deposition within
glomeruli and vessels. Associated coagulation disorders
in the mink suggest a prolonged state of intravascular
coagulation [57]. In NZB mice the importance of coagula-
tion as an intermediary mechanism is shown by massive
fibrin deposition and resulting rapid progress of the lesions
following injection of DNA when anti-DNA antibodies are
circulating [54].
The participation of local coagulation in renal vessels
and glomeruli in other forms of experimental glomerulo-
nephritis has been well documented and reviewed by Vassalli
and McCluskey [5, 58].
Fibrin deposition has also been shown to be a universal
and important pathogenetic mechanism in long-surviving
allografts in rats. Here the trigger mechanism initiating
fibrin deposition does not seem to be immunoglobulin
deposition [65].
Renal lesions in man: the nature of the underlying damage.
In most disorders in this group there is demonstrable
immunological damage. However, polyarteritis nodosa
which shows only fibrin and no immunoglobulin in vessels
and glomeruli occupies an intermediate position between
the disorders discussed above and those discussed in this
section.
Although immunoglobulins can be demonstrated in most
other lesions, they may be absent. For example, patients
with hypocomplementemia may show heavy complement
deposits in glomeruli and little or no associated immuno-
globulin. It has been postulated that glomerular damage
may result from activation of the complement system by
some non-immunological mechanism, for example, by
properdin which is present in all cases of chronic mesangio-
capillary (membranoproliferative) glomerulonephritis [59].
Deposits of fibrin or fibrinoid material and fibrin degrada-
tion products in the serum. Fibrinoid material is commonly
deposited within glomeruli and it probably represents a
fibrin monomer or some other fibrin breakdown product
[6]. It resembles the granular fibrinoid material that is
found after the infusion of thromboplastin [3] and it has
the appearance of fibrin that is precipitated in the presence
of degradation products in vitro [60]. It shows positive
staining by immunofluorescent techniques [5].
In a group of patients with idiopathic and specific forms
of glomerulonephritis we found a positive correlation
between the activity of glomerular lesions and the level of
fibrin degradation products inthe serum [61, 621. Among
128 patients with idiopathic glomerulonephritis, only 12%
of those with inactive lesions showed elevated fibrin degra-
dation products in the serum. Whereas in diffuse mesan-
giocapillary (membranoproliferative) glomerulonephritis
51.6% had elevated fibrin degradation products, and this
figure was even higher (70%) in patients with active lesions
associated with fibrin and crescents in glomeruli [62],
these findings have been confirmed [63].
Levels of fibrin degradation products correlated well
with fibrin on immunofluorescent studies and electron
microscopy, and also with clinical features suggesting active
186 Kincaid-Smith
disease such as heavy proteinuria, renal functional deteri-
oration and haematuria [61, 62].
The level of fibrin degradation products in the serum
correlates well with episodes of rejection in renal allografts
[62, 64]. Fibrin is a prominent feature in allografts both in
acute rejection and in long-standing allografts [38, 39].
Biopsies at the time of grafting and repeatedly thereafter
have permitted us to study the pathogenesis of the vascular
and glomerular lesions in allografts. Organization of the
products of coagulation seems to play an important part
in acute and chronic allograft rejection [8, 38, 39, 65]. In
long-standing allografts, the lesions of rejection may closely
resemble those of chronic mesangiocapillary glomerulo-
nephritis in patients whose original disease was not glomeru-
lonephritis (39, and unpublished observations of the author).
Merrill has reviewed the possible factors contributing to
this appearance [65]. The same changes develop in long-
standing allografts in rats [65], suggesting that they are
related perhaps more closely to the organization of fibrin
(which is a universal and prominent feature in such kidneys)
than to glomerulonephritis arising de novo in the transplant.
Fibrin deposition does not seem to depend upon immuno-
globulin deposition [65].
Translucent subendothelial deposits may provide an
important marker of active deposition and lysis of fibrin
in glomeruli [8, 66]. Habib et a! (67] described these lesions
in the hemolytic-uremic syndrome in childhood and others
found similar changes in adults [68]. These translucent
zones are present in a wide variety of different disorders in
which the common factor seems to be active deposition and
lysis of fibrin within glomerular capillaries. They are promi-
nent and widespread in the thrombotic microangiopathies
but are also found in acute allograft rejection, active
proliferative glomerulonephritis, pre-eclamptic toxemia
[8, 39, 42, 66] and in acute tubular necrosis [69]. Patients
in whom this change is pronounced often have a poor
prognosis; however, if resolution does occur, collagen fibres
within the capillary wall may be prominent in the healing
stages [8, 39, 66].
Treatment with antithrombotic and anticoagulant agents
The most important aspect of the participation of coagu-
lation in the etiology of renal failure and the pathogenesis
of renal lesions is the possible application of this knowledge
to treatment.
Animal experiments. In experimental nephritis where
treatment can be started before the lesions develop, the
effects of anticoagulants have been dramatic. Not only do
warfarin or heparin in adequate doses prevent deposition of
fibrin or fibrinoid material, but they prevent glomerular
sclerosis and crescent formation and progressive oblitera-
tion of glomeruli despite persisting immunoglobulin deposi-
tion and proteinuria [5, 58, 70]. Fibrinolytic agents have
been even more effective than heparin in mice [71]. Like-
wise in the highly fatal form of "lupus" nephritis in NZB
mice, Lambert [54] demonstrated marked alleviation of the
histological lesions as well as significant prolongation
of survival in mice treated with a daily injection of
heparin.
In relation to the systemic forms of intravascular coagula-
tion discussed above, both heparin [21] and warfarin [72]
will prevent the Sanarelli-Schwartzman reaction. The im-
portance of vasoactive factors in the pathogenesis of lesions
and the possible role of platelets in causing and perpetuat-
ing vascular spasm means that both x-blocking agents and
anti-thrombotic agents may increase the effectiveness of
anticoagulant treatment.
Results of treatment with antithrombotic and anti-coagu-
lant agents in man. Prospective controlled studies of anti-
coagulant treatment in man have not yet been reported but
results of treatment which have been reported suggest that
treatment with anticoagulants alone or in combination
with antithrombotic or immunosuppressive agents may
prove very useful in the treatment of various forms of
renal disease [39, 44, 45, 66, 73—86].
There are several different groups of patients in which
anticoagulants have been used alone or in combination with
antithrombotic agents. In severe acute renal failure assoc-
iated with diffuse glomerular or vascular lesions in adults,
the reported prognosis without treatment or with steroids
has been very poor [76]. As this clinical setting seems to
provide one of the major indications for heparin therapy,
and as the results of such treatment have usually been
much better than previous therapeutic experience in this
rapidly fatal group, we have been reluctant to set up pro-
spective controlled studies in such patients [76]. Such studies
can best be carried out by those who doubt the value of
heparin therapy. Any one unit sees only an occasional
patient with severe acute renal failure due to diffuse glomeru-
lar or vascular lesions; thus, a multi-center study with all
of its incumbent disadvantages and difficulties would be
necessary. Animal experiments and the rapid destruction of
glomeruli which may occur in such patients indicate that
early treatment is important and provision for this should be
included in any controlled study that may be initiated.
An individual patient may show repeated response to
heparin and subsequent deterioration when heparin is
withdrawn; thus, such patients may act is their own control
[76, 78]. Although this establishes that heparin is of benefit
in improving renal function in individual patients, it does
not provide an answer for the whole group of patients.
Another condition in which an acute onset is associated
with widespread fibrin deposition is that of pre-eclamptic
toxemia [40,41]. The indication for heparin in such patients
is to enable the pregnancy to continue and to permit
survival of the baby. In severe pre-eclamptic toxemia which
develops early in the third trimester, fetal loss is almost
invariable. Heparin has been used in such cases with
apparent success [80].
In acute allograft rejection infusion of heparin has pro-
duced an improvement in renal function and renal blood
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flow and these have deteriorated again after the withdrawal
of heparin [81, 821. In the gradual rejection which occurs in
many cadaveric renal allografts, early results of treatment
have [39, 87] encouraged us to set up a long-term prospec-
tive controlled trial of treatment which is still in progress
and may still need to be continued for several years. It is
possible that histological changes in serial biopsy specimens
may show significant differences before clinical differences
are apparent.
The most difficult group of all in which to assess any
benefit from anticoagulant treatment is that of progressive
chronic glomerulonephritis. In recent years general agree-
ment has been reached about the classification of glomerulo-
nephritis on a morphological basis. It has also been
possible to better define the natural history of various
forms of glomerulonephritis [88]. In many different forms
of progressive glomerulonephritis the five year survival is
reasonably good but 10 year survival is very poor. Pro-
spective controlled trials in such patients would therefore
need to be continued for five years or longer before one
could expect to see significant alterations in survival as a
result of treatment.
The only groups in which an answer might be obtained
from shorter treatment periods are those in whom the
prognosis is known to be grave. This has been so in adults
with the nephrotic syndrome, hypertension and poor renal
function with mesangiocapillary (membranoproliferative)
glomerulonephritis [89—91]. A retrospective analysis of
such patients presenting to this unit showed a highly
significant (P<0.001) prolongation of survival in 16 patients
treated for periods of 4 to 44 months with combined anti-
coagulants, dipyridamole and cyclophosphamide as com-
pared with a similar group of 13 patients who were not
treated in this way [92]. Renal function improved in 10 of
16 treated patients and five patients showed disappearance
of proteinuria and microscopic haematuria and loss of the
characteristic double contour appearance in glomerular
capillaries [92].
Cade et al [85] have reported similar findings in a group
of patients with chronic proliferative glomerulonephritis
treated with long-term heparin. Michielsen and his group
[93-95] and others [96] have reported a fall in fibrin
degradation products and improvement in histological
lesions in chronic proliferative glomerulonephritis with
indomethacin. The abnormalities reappeared after with-
drawal of indomethacin. Whether this effect is related to
the antithrombotic action of indomethacin or to its anti-
inflammatory properties is not certain. The complicated
interrelations between the inflammatory response and
mechanisms of coagulation have recently been reviewed
by McKay [97]. Heparin and antithrombotic agents such
as dipyridamole and prostaglandin E will prevent in-
flammatory responses such as the Arthus reaction [97].
Inflammation in such conditions as gouty arthropathy
depends upon activation of the Hagemann factor by urate
crystals [98], and inflammatory mechanisms at present
poorly understood could play an important role in glomer-
ulonephritis.
The role of complement in glomerulonephritis is also
under close scrutiny. Complement plays a significant role
in both immune and non-immune inflammation [99] and
it has been suggested that complement may cause glomer-
ular injury through mechanisms unrelated to the antigen-
antibody reactions [59]. The chemotactic effects of comple-
ment may lead to damage of the basement membrane by
granulocytes and this in turn could lead to intravascular
coagulation.
Whatever triggers intravascular coagulation in glomer-
ulonephritis there is little doubt that coagulation parti-
cipates in progressive damage. The role of antithrombotic
and anticoagulant drugs has not yet been clearly defined.
They are, however, the only agents which have been shown
to improve function, reverse proteinuria and microscopic
haematuria and improve histological lesions in patients
with serious progressive forms of glomerulonephritis.
Because glomerulonephritis is the commonest cause of
renal failure in patients presenting for dialysis and trans-
plantation, there is a great need for prospective trials of
antithrombotic and anticoagulant drugs in glomerulon-
ephritis. Unfortunately, such studies are unlikely to yield
results in less than five years unless well defined groups of
patients with a poor prognosis are studied.
Priscilla Kincaid-Smith
Victoria, Australia
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